Zoetis Inc. Class A
As of Oct 22, 2026, Zoetis is in Stage 4, the downtrend phase, now in week 30 (since Mar 24, 2026). It closed at $82.00, 43.4% below its 52-week high and below its 200-day average, which is falling.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health s… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is ZTS early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
ZTS among Drug Manufacturers - Specialty & Generic55th of 84 by relative strength
All 84 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CPIX | Stage 2 · wk 23 | 98 | +6.8% |
| 2 | ETON | Stage 2 · wk 30 | 97 | −10.1% |
| 3 | ANIK | Stage 2 · wk 15 | 96 | +3.5% |
| 4 | IRWD | Stage 3 · wk 3 | 96 | −16.4% |
| 5 | TEVA | Stage 2 · wk 9 | 95 | +3.1% |
| 6 | AMRX | Stage 2 · wk 19 | 95 | +5.9% |
| 7 | KNSA | Stage 2 · wk 73 | 95 | +6.2% |
| 8 | AMLX | Stage 2 · wk 15 | 93 | −6.6% |
| …55 | ZTS | Stage 4 · wk 30 | 27 | +14.5% |
Zoetis: quick answers
What stage is Zoetis in?
As of Oct 22, 2026, Zoetis (ZTS) is in Stage 4, the downtrend phase. It entered Stage 4 on Mar 24, 2026 and is in week 30. What the four stages mean
Is Zoetis in an uptrend?
No. Zoetis is in a Stage 4 downtrend. It trades 13.0% below its 200-day average, which is falling.
How far is Zoetis from its 52-week high?
Zoetis closed at $82.00 on Oct 22, 2026, 43.4% below its 52-week high of $144.75. Its 52-week low is $69.10.
How has Zoetis performed over the past year?
As of Oct 22, 2026, Zoetis is down 42.8% over the past year and down 33.9% so far in 2026.
Which sector and industry is Zoetis in?
Zoetis is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - Specialty & Generic
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.